Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study

Johnson, Peter; Challis, Ruth; Chowdhury, Ferdousi; Gao, Yifang; Harvey, Melanie; Geldart, Tom; Kerr, Paul; Claude Chan, H.T.; R. Smith, Anna; Steven, Neil; Edwards, Ceri; Ashton‐Key, Margaret; Hodges, Elisabeth; Tutt, Alison; H. Ottensmeier, Christian; J. Glennie, Martin; P. Williams, Anthony

doi:10.1158/1078-0432.ccr-14-2355

Public

Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study

Published in Clinical Cancer Research • Jan 15, 2015

Authors:

Peter Johnson

Ruth Challis

Ferdousi Chowdhury

Abstract

PURPOSE: This phase I study aimed to establish the biologic effects and MTD of the agonistic IgG1 chimeric anti-CD40 antibody ChiLob7/4 in patients (pts) with a range of CD40-expressing solid tumors and diffuse large B-cell lymphoma, resistant to conventional therapy. Potential mechanisms of action ...

Subject

Medicine

Pharmacology

Pharmacodynamics

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!